Enterome scientists contribute to extensive new genomic and proteomic catalog to enhance analysis of the gut microbiome and understanding of its role in human health
Read more
30
July 2020
Enterome initiates first clinical trial with EO2401 – an innovative microbiome-antigen (‘OncoMimic’) based cancer immunotherapy candidate targeting aggressive brain cancer
Read more
25
June 2020
Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline
Read more
03
February 2020
Enterome collaborates with BIOASTER Institute to provide new insights into mechanisms of potential microbiome-derived cancer immunotherapies
Read more
07
November 2019
Enterome enters research collaboration with major cancer center focused on new microbiome-derived immunotherapies
Read more
03
April 2019
Enterome expands and strengthens its management team
Read more
27
March 2019
Enterome to present data on its innovative microbiome-derived molecular mimicry approach to cancer immunotherapy at AACR 2019
Read more
20
March 2019
Enterome announces research collaboration with renowned US Cancer Institute focused on new microbiome-derived cancer immunotherapy
Read more
23
October 2018
Enterome signs global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease
